GS Effex® Cell Line for Enhanced Antibody Effector Function

How it works

Produce more potent and effective cytotoxic therapeutic antibodies

The interaction of the IgG antibody Fc region with Fc receptors on immune effector cells engages antibody-dependent cellular cytotoxicity (ADCC) to induce target cell death. Removal of fucose residues on the Fc region has been shown to enhance ADCC, increasing the potency of antibody immunotherapies.

GS Effex®, derived from Lonza’s leading GS Xceed® cell line, has been engineered to lack the enzyme responsible for the addition of fucose, α1,6-fucosyltransferase. This industrially relevant cell line produces antibodies free of fucose, yet retains all of the desirable performance attributes of GS Xceed®.

Download the flyer

Access to industry-leading technologies

GS Effex^® is available to license as part of Lonza’s GS Gene Expression System^®. A plug and play addition to the GS^® toolbox, it is fully compatible with GS^® workflows and processes.